Marizyme, Inc. (MRZM)
OTCMKTS: MRZM · Delayed Price · USD
0.0533
-0.0008 (-1.48%)
Jun 20, 2024, 12:00 AM EDT - Market closed
Marizyme Revenue
Marizyme had revenue of $549.69K in the twelve months ending March 31, 2024, with 51.66% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $32.86K, a -74.53% decrease year-over-year. In the year 2023, Marizyme had annual revenue of $645.81K with 176.60% growth.
Revenue (ttm)
$549.69K
Revenue Growth
+51.66%
P/S Ratio
12.78
Revenue / Employee
$42,284
Employees
13
Market Cap
7.02M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 645.81K | 412.33K | 176.60% |
Dec 31, 2022 | 233.49K | 23.21K | 11.04% |
Dec 31, 2021 | 210.28K | 13.14K | 6.67% |
Dec 31, 2020 | 197.14K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 20.19K | -80.99K | -80.05% |
Dec 31, 2017 | 101.18K | -189.96K | -65.25% |
Dec 31, 2016 | 291.14K | -116.57K | -28.59% |
Dec 31, 2015 | 407.71K | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 25.81M | -1.90M | -6.86% |
Mar 31, 2012 | 27.71M | 27.69M | 199,577.33% |
Mar 31, 2010 | 13.88K | -24.59K | -63.92% |
Mar 31, 2009 | 38.46K | 6.90K | 21.85% |
Mar 31, 2008 | 31.57K | 20.39K | 182.56% |
Mar 31, 2007 | 11.17K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
MRZM News
- 2 months ago - Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ - GlobeNewsWire
- 9 months ago - Marizyme CEO Delivers Business Update - GlobeNewsWire
- 9 months ago - Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™ - GlobeNewsWire
- 1 year ago - Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products - GlobeNewsWire
- 2 years ago - Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office - GlobeNewsWire
- 2 years ago - Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing - GlobeNewsWire
- 2 years ago - Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress - GlobeNewsWire
- 2 years ago - Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories - GlobeNewsWire